Major Depressive Disorder Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, and Treatment Algorithm | Key Companies - Axsome Therapeutics (Auvelity),

As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Major Depressive Disorder therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Major Depressive Disorder Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Major Depressive Disorder Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Major Depressive Disorder Pipeline Analysis
The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Major Depressive Disorder Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Major Depressive Disorder market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Key Developments in the Major Depressive Disorder Therapeutics Market
• On August 19, 2022, Axsome Therapeutics, Inc. (NASDAQ: AXSM) announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITYTM (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of the major depressive disorder (MDD) in adults.

DelveInsight's Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/report-store/major-depressive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Major Depressive Disorder Therapeutic Outlook
There are approx. 75+ key companies which are developing therapies for Major Depressive Disorder. Currently, SAGE Therapeutics has its Major Depressive Disorder drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Major Depressive Disorder Therapeutic Market include:
• GH Research
• Axsome Therapeutics
• Praxis Precision Medicines
• AbbVie
• Gedeon Richter
• Intra-Cellular Therapies
• Bristol-Myers Squibb
• Relmada Therapeutics
• SAGE Therapeutics
• Janssen Research & Development
• Minerva Neurosciences
• Takeda
• Neurocrine Biosciences
• Pherin Pharmaceuticals
• Axsome Therapeutics
• Johnson & Johnson
And many others

Major Depressive Disorder Emerging Drugs Covered in the report include:
• SAGE-217: Sage Therapeutics
• REL-1017: Relmada Therapeutics, Inc
• Seltorexant: Minerva Sciences
• SP-624: Sirtsei Pharmaceuticals, Inc.
• SPL026: Small Pharma
• PDC-1421: BioLite Inc
And many more

Download Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Major Depressive Disorder Current Treatment Patterns
4. Major Depressive Disorder - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Major Depressive Disorder Late Stage Products (Phase-III)
7. Major Depressive Disorder Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Major Depressive Disorder Discontinued Products
13. Major Depressive Disorder Product Profiles
14. Major Depressive Disorder Key Companies
15. Major Depressive Disorder Key Products
16. Dormant and Discontinued Products
17. Major Depressive Disorder Unmet Needs
18. Major Depressive Disorder Future Perspectives
19. Major Depressive Disorder Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request the Sample PDF to Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/major-depressive-disorder-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.